Patent US5331573A successfully refreshed from Google Patents.
US5331573A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of design of compounds that mimic conformational features of selected peptides
Assignee: Individual
•
Filing: 1990-12-14
•
Granted: 1994-07-19
•
Expires: 2010-12-14
Abstract
Abstract A method of rational drug design includes simulating polypeptides in a way that predicts the most probable secondary and/or tertiary structures of a polypeptide, e.g., an oligopeptide, without any presumptions as to the conformation of the underlying primary or secondary structure. The method involves computer simulation of the polypeptide, and more particularly simulating a real-size primary structure in an aqueous environment, shrinking the size of the polypeptide isobarically and isothermally, and expanding the simulated polypeptide to its real size in selected time periods. A useful set of tools, termed Balaji plots, energy conformational maps, and probability maps, assist in identifying those portions of the predicted peptide structure that are most flexible or most rigid. The rational design of novel compounds, useful as drugs, e.g., bioactive peptidomimetic compounds, and constrained analogs thereof, is thus made possible using the simulation methods and tools of the described invention.
Inventors
- 👤 Vitukudi N. Balaji
- 👤 Chandra U. Singh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 07:06
CPC Classifications
C; C07; C07K; C07K16/00; G; G16; G16B; G16B15/00; G16B15/20
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
138 words
A method for producing simulated, chemically modified peptide or peptidomimetic structure(s) which substantially mimic the energetically most probable three-dimensional structure of preselected less constrained polypeptide(s), said method comprising: (1) determining the φ and ψ angles for each residue included in the preselected polypeptide; (2) comparing the φ and ψ angles for each residue obtained in step (i) with the φ and ψ angles for each residue of known polypeptide species; (3) substituting a chemically modified moiety for at least one of the residues of the preselected polypeptide to produce a chemically modified peptide or peptidomimetic structure, wherein said chemically modified moiety has φ and ψ angles which are substantially similar to the φ and ψ angles of the residue that is replaced; and (4) chemically synthesizing and testing the bioactivity of the chemically modified peptide or peptidomimetic structure.
Claim 2
Independent Claim
138 words
A method for producing simulated, chemically modified peptide or peptidomimetic structure(s) which substantially mimic the energetically most probable three-dimensional structure of preselected less constrained polypeptide(s), said method comprising: (1) determining the φ and ψ angles for each residue included in the preselected polypeptide; (2) comparing the φ and ψ angles for each residue obtained in step (i) with the φ and ψ angles for each residue of known polypeptide species; (3) substituting a chemically modified moiety for at least one of the residues of the preselected polypeptide to produce a chemically modified peptide or peptidomimetic structure, wherein said chemically modified moiety has φ and ψ angles which are substantially similar to the φ and ψ angles of the residue that is replaced; and (4) chemically synthesizing and testing the bioactivity of the chemically modified peptide or peptidomimetic structure.
Claim 3
Dependent Claim
51 words
The method of claim 1, wherein steps (1), (2), and (3) are repeated sequentially, beginning with a first residue of the preselected, less constrained polypeptide, so as to produce chemically modified analog(s) having a tertiary structure that substantially mimics the energetically most probable tertiary structure of the preselected, less constrained polypeptide(s).
Claim 4
Independent Claim
160 words
A method for generating biologically or pharmacologically active molecules, comprising: (a) determining the amino acid sequence of the hypervariable region of a monoclonal antibody having biological or phamacological activity, and (b) producing a peptidomimetic compound based on the amino acid sequence of step (a), wherein the peptidomimetic compound substantially retains the biological or pharmacological activity of said monoclonal antibody, wherein said peptidomimetic compound is produced by: (i) determining the energetically most probably φ and ψ angles for each residue included in the hypervariable region of said monoclonal antibody, (ii) comparing the φ and ψ angles for each residue obtained in step (i) with the φ and ψ angles for each residue of known polypeptide species, and (iii) substituting a chemically modified moiety for at least one of the residues of the pharmaceutically active compound, wherein said chemically modified moiety has φ and ψ angles which are substantially similar to the φ and ψ angles of the residue to be replaced.
Claim 5
Independent Claim
160 words
A method for generating biologically or pharmacologically active molecules, comprising: (a) determining the amino acid sequence of the hypervariable region of a monoclonal antibody having biological or phamacological activity, and (b) producing a peptidomimetic compound based on the amino acid sequence of step (a), wherein the peptidomimetic compound substantially retains the biological or pharmacological activity of said monoclonal antibody, wherein said peptidomimetic compound is produced by: (i) determining the energetically most probably φ and ψ angles for each residue included in the hypervariable region of said monoclonal antibody, (ii) comparing the φ and ψ angles for each residue obtained in step (i) with the φ and ψ angles for each residue of known polypeptide species, and (iii) substituting a chemically modified moiety for at least one of the residues of the pharmaceutically active compound, wherein said chemically modified moiety has φ and ψ angles which are substantially similar to the φ and ψ angles of the residue to be replaced.
References Cited (Backward Citations)
US4881175A
Cited
US4853871A
Cited
US4908773A
Cited
US4852017A
Cited
US4939666A
Cited
US5081584A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-07-18 | 1998-01-17 | 1998-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-07-18 | 2002-01-17 | 2002-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-07-18 | 2006-01-17 | 2006-07-19 | $7700.00 | Window Closed / Lapsed |